Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Rigosertib in Transfusion-dependent Low/Int-1 Risk MDS
NCT01904682Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Jul 2013
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by Traws Pharma, Inc.. Started Jul 2013; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01904682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01904682.